Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome

Journal of Neuroimmunology

Volumn 197, Issue 1, 2008, Pages 47-53

  Martin Moutot, Nicole ^a,b   De Haro, Luc ^a,b   Seagar, Michael ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Autoimmune diseases; Calcium channel; Lambert Eaton myasthenic syndrome; Neuromuscular diseases; Paraneoplastic syndromes

Indexed keywords

3,4 DIAMINOPYRIDINE; ANTINEOPLASTIC AGENT; AUTOANTIBODY; CALCIUM CHANNEL N TYPE ANTIBODY; CALCIUM CHANNEL P TYPE ANTIBODY; CALCIUM CHANNEL Q TYPE ANTIBODY; GUANIDINE; IMMUNOGLOBULIN; PROTEIN ANTIBODY; PYRIDOSTIGMINE; STEROID;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EATON LAMBERT SYNDROME; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOLECULAR EVOLUTION; PLASMAPHERESIS; PRIORITY JOURNAL;

AGED; AUTOANTIBODIES; CALCIUM CHANNELS, N-TYPE; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; EVOLUTION, MOLECULAR; FEMALE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 44649143822     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.001     Document Type: Article

References (31)

1. Bady B., Vial C., and Chauplannaz G. [Lambert-Eaton syndrome: clinical and electrophysiological study of 18 cases associated with lung cancer]. Rev. Neurol. (Paris) 148 (1992) 513-519
2. Comola M., Nemni R., Sher E., Quattrini A., Faravelli A., Comi G., Corbo M., Clementi F., and Canal N. Lambert-Eaton myasthenic syndrome and polyneuropathy in a patient with epidermoid carcinoma of the lung. Eur. Neurol. 33 (1993) 121-125
3. Flink M.T., and Atchison W.D. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission. J. Physiol. 543 (2002) 567-576
4. 2+ channelopathies. J. Bioenerg. Biomembranes 35 (2003) 697-718
5. Giovannini F., Sher E., Webster R., Boot J., and Lang B. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br. J. Pharmacol. 136 (2002) 1135-1145
6. Gold R., Stangel M., and Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3 (2007) 36-44
7. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J. Neurol. 252 1 (2005) I14-I18
8. Ionescu D.N., Treaba D., Gilks C.B., Leung S., Renouf D., Laskin J., Wood-Baker R., and Gown A.M. Nonsmall cell lung carcinoma with neuroendocrine differentiation - an entity of no clinical or prognostic significance. Am. J. Surg. Pathol. 31 (2007) 26-32
9. Lang B., and Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun. Rev. 2 (2003) 94-100
10. Lennon V.A., and Lambert E.H. Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome. Mayo Clin. Proc. 64 (1989) 1498-1504
11. Leys K., Lang B., Johnston I., and Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. Neurol. 29 (1991) 307-314
12. Maddison P., Newsom-Davis J., Mills K.R., and Souhami R.L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 (1999) 117-118
13. Martin-Moutot N., Leveque C., Sato K., Kato R., Takahashi M., and Seagar M. Properties of omega conotoxin MVIIC receptors associated with alpha 1A calcium channel subunits in rat brain. FEBS Lett. 366 (1995) 21-25
14. Martin-Moutot N., de Haro L., and Seagar M. [Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome]. Rev. Neurol. (Paris) 160 (2004) S28-S34
15. Martin-Moutot N., Haro L., Santos R.G., Mori Y., and Seagar M. Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome. Neurobiol. Dis. 22 (2006) 57-63
16. Motomura M., Lang B., Johnston I., Palace J., Vincent A., and Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 147 (1997) 35-42
17. Nakao Y.K., Motomura M., Suenaga A., Nakamura T., Yoshimura T., Tsujihata M., Mori M., Itoh M., and Nagataki S. Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J. Neurol. 246 (1999) 38-44
18. Nakao Y.K., Motomura M., Fukudome T., Fukuda T., Shiraishi H., Yoshimura T., Tsujihata M., and Eguchi K. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59 (2002) 1773-1775
19. Oh S.J., Kim D.S., Head T.C., and Claussen G.C. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 20 (1997) 1146-1152
20. Oh S.J., Kurokawa K., Claussen G.C., and Ryan Jr. H.F. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32 (2005) 515-520
21. Pinto A., Gillard S., Moss F., Whyte K., Brust P., Williams M., Stauderman K., Harpold M., Lang B., Newsom-Davis J., Bleakman D., Lodge D., and Boot J. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8328-8333
22. Protti D.A., Reisin R., Mackinley T.A., and Uchitel O.D. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology 46 (1996) 1391-1396
23. Sanders D.B. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann. N. Y. Acad. Sci. 998 (2003) 500-508
24. Santafe M.M., Urbano F.J., Lanuza M.A., and Uchitel O.D. Multiple types of calcium channels mediate transmitter release during functional recovery of botulinum toxin type A-poisoned mouse motor nerve terminals. Neuroscience 95 (2000) 227-234
25. Sher E., Gotti C., Canal N., Scoppetta C., Piccolo G., Evoli A., and Clementi F. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 2 (1989) 640-643
26. Takamori M., Takahashi M., Yasukawa Y., Iwasa K., Nemoto Y., Suenaga A., Nagataki S., and Nakamura T. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 133 (1995) 95-101
27. Tchouhadjian C., Barlesi F., Doddoli C., Escarguel B., Thomas P., Witjas T., Astoul P., and Kleisbauer J.P. [Difficulties associated with Lambert-Eaton syndrome]. Rev. Mal. Respir. 21 (2004) 1167-1170
28. Tim R.W., Massey J.M., and Sanders D.B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 54 (2000) 2176-2178
29. 2+ channels. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3491-3496
30. Voltz R., Carpentier A.F., Rosenfeld M.R., Posner J.B., and Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 22 (1999) 119-122
31. Wirtz P.W., Lang B., Graus F., van den Maagdenberg A.M., Saiz A., de Koning Gans P.A., Twijnstra A., and Verschuuren J.J. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J. Neuroimmunol. 164 (2005) 161-165